bioMérieux S.A. (EPA:BIM)
71.85
+0.75 (1.05%)
May 11, 2026, 5:35 PM CET
bioMérieux Revenue
In the year 2025, bioMérieux had annual revenue of 4.07B EUR with 2.26% growth. bioMérieux had revenue of 2.03B in the half year ending December 31, 2025, with 6.37% growth.
Revenue
4.07B
Revenue Growth
+2.26%
P/S Ratio
2.06
Revenue / Employee
273.25K
Employees
15,226
Market Cap
8.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.07B | 89.90M | 2.26% |
| Dec 31, 2024 | 3.98B | 305.20M | 8.31% |
| Dec 31, 2023 | 3.67B | 85.60M | 2.38% |
| Dec 31, 2022 | 3.59B | 212.90M | 6.31% |
| Dec 31, 2021 | 3.38B | 258.00M | 8.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 47.35B |
| EssilorLuxottica Société anonyme | 28.49B |
| Eurofins Scientific SE | 7.30B |
| emeis Société anonyme | 5.90B |
| Ramsay Générale de Santé | 5.36B |
| Clariane SE | 5.31B |
| Ipsen | 3.93B |
| Sartorius Stedim Biotech | 2.98B |
bioMérieux News
- 17 days ago - bioMerieux price target lowered to EUR 71.60 from EUR 120.50 at JPMorgan - TheFly
- 17 days ago - bioMerieux downgraded to Hold from Buy at Deutsche Bank - TheFly
- 18 days ago - bioMérieux Earnings Call Transcript: Q1 2026 - Transcripts
- 18 days ago - BioMerieux Q1 Sales Down 3.9% On Organic Basis; Revises 2026 Guidance - Nasdaq
- 27 days ago - bioMerieux price target lowered to EUR 100 from EUR 108 at Morgan Stanley - TheFly
- 2 months ago - bioMérieux Earnings Call Transcript: H2 2025 - Transcripts
- 2 months ago - bioMerieux price target lowered to EUR 100 from EUR 110 at Barclays - TheFly
- 3 months ago - bioMerieux price target lowered to EUR 109 from EUR 112 at Morgan Stanley - TheFly